Myriad Pharmaceuticals, Inc.'s Tablet Formulation of MPC-4326 Reduces Viral Load in HIV-1 Patients

September 14, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

SALT LAKE CITY, Sept. 14, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the presentation of two abstracts detailing positive data for MPC-4326, its novel maturation inhibitor for the treatment of HIV infection.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2